Avadel Pharmaceuticals
16640 Chesterfield Grove Road, Suite 200
Chesterfield
MO
63005
United States
Website: https://www.avadel.com/
303 articles about Avadel Pharmaceuticals
-
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences - March 5, 2024
3/5/2024
Avadel Pharmaceuticals plc announced today that members of management will participate in the following upcoming investor conferences.
-
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
3/4/2024
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the fourth quarter ended December 31, 2023.
-
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 4
2/26/2024
Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that it will host a conference call and live webcast at 7:30 a.m. ET on Monday, March 4, 2024, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2023.
-
Avadel Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/7/2024
Avadel Pharmaceuticals plc announced today that members of management will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14 at 2:00 p.m. ET.
-
Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights
1/8/2024
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, provided a business update including preliminary estimates of fourth quarter and full year net revenue and cash, cash equivalents and marketable securities.
-
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
11/8/2023
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the third quarter ended September 30, 2023.
-
Avadel Pharmaceuticals to Present at Upcoming November 2023 Investor Conferences
11/7/2023
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced that members of management will participate in the following upcoming investor conferences.
-
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 8
10/30/2023
Avadel Pharmaceuticals plc announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 8, 2023, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2023.
-
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023
10/20/2023
Avadel Pharmaceuticals plc today announced new and encore data supporting the clinical profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) and patient preference for a once-nightly oxybate in 15 poster presentations and two oral presentations, at World Sleep 2023, being held from October 20-25, 2023 in Rio de Janeiro, Brazil.
-
Avadel Pharmaceuticals to Present at the Jefferies Biotech CNS/Neuro Summit
10/5/2023
Avadel Pharmaceuticals plc announced today that members of management will participate in a fireside chat at the Jefferies Biotech CNS/Neuro Summit on Thursday, October 12 at 9:00 a.m. ET.
-
Avadel Pharmaceuticals to Present at Upcoming September 2023 Investor Conferences
8/31/2023
Avadel Pharmaceuticals plc announced that members of management will participate in the following upcoming investor conferences:
-
Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8/9/2023
Avadel Pharmaceuticals plc today provided a corporate update and announced its financial results for the second quarter ended June 30, 2023.
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - August 03, 2023
8/3/2023
Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three new employees to purchase an aggregate of 26,000 ordinary shares under Avadel’s 2021 Inducement Plan.
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - July 20, 2023
7/20/2023
Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three new employees to purchase an aggregate of 20,000 ordinary shares under Avadel’s 2021 Inducement Plan.
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - July 06, 2023
7/6/2023
Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to nine new employees to purchase an aggregate of 90,000 ordinary shares under Avadel’s 2021 Inducement Plan.
-
Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIII
6/22/2023
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a Commercial Day presentation to provide an overview of its commercial strategy for recently launched LUMRYZ on Thursday, June 29, 2023 beginning at 8:00 a.m. ET.
-
Avadel Pharmaceuticals Sponsors the Academy of Sleep Medicine Foundation’s 2023 Young Investigators Research Forum
6/14/2023
Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced leader sponsorship of the American Academy of Sleep Medicine Foundation’s 15th Annual Young Investigators Research Forum.
-
Avadel Pharmaceuticals Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-at-Bedtime Oxybate Dosing for Narcolepsy
6/13/2023
Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced the publication of survey data describing clinician preferences among oxybate treatments for patients living with narcolepsy.
-
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - June 06, 2023
6/6/2023
Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to fifteen new employees to purchase an aggregate of 129,000 ordinary shares under Avadel’s 2021 Inducement Plan.
-
Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ™ (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy
6/5/2023
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZ is now commercially available.